2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Lymphoma, Follicular
18
Sarcoma
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, B-Cell
7
Rhabdoid Tumor
6
Lymphoma, Non-Hodgkin
6
Sarcoma, Synovial
5
Lymphoma
5
Prostatic Neoplasms
4
Recurrence
3
Mesothelioma
3
Lymphoma, Mantle-Cell
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Hematologic Neoplasms
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Xanthogranuloma, Juvenile
1
Urinary Bladder Neoplasms
1
Interventions
tazemetostat
1
relatlimab
1
regorafenib
1
durvalumab
1
brigimadlin
1
bintrafusp alfa protein, human
1
Nivolumab
1
Doxorubicin
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Tertiary Lymphoid Structures
×
tazemetostat
×
Clear all
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled